ASEAN Contract Development and Manufacturing Organization (CDMO) Market Size, Pharma Outsourcing Trends and Forecast 2026–2034

ASEAN Contract Development and Manufacturing Organization (CDMO) Market Overview By Fortune Business Insights

Market Summary

According to Fortune Business Insights: The ASEAN Contract Development and Manufacturing Organization (CDMO) market was valued at USD 9.43 billion in 2020 and is projected to grow from USD 10.91 billion in 2021 to USD 22.53 billion by 2028, at a robust CAGR of 10.9% over the forecast period. A CDMO is an organization that serves pharmaceutical companies on a contract basis, offering services spanning drug development through to full-scale manufacturing. The growing trend of outsourcing by both large and small pharmaceutical companies presents significant opportunities for the ASEAN CDMO sector, particularly as pharmaceutical companies increasingly shift resources toward research and development rather than in-house manufacturing.

The ASEAN region offers compelling advantages for contract manufacturing, including lower production costs, tax incentives, and a skilled labor pool. These factors have encouraged leading western CDMOs and multinational pharmaceutical companies to establish or expand operations across the region. A notable example is U.S. biopharmaceutical company AbbVie Inc., which opened a biologics manufacturing facility at the Tuas Biomedical Park in Singapore in August 2017.

Get a Sample Research PDF: https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/106193

Key Market Trends

The most prominent trend shaping the ASEAN CDMO landscape is industry consolidation through mergers and acquisitions. The sector remains highly fragmented, with numerous local and global players — many of which are privately held or backed by private equity. However, this is changing rapidly, with large global strategic investors taking increasing interest in the space. According to Ernst & Young, the number of publicly announced global CDMO deals rose approximately 12% per year since 2012. A landmark example is ICON plc's February 2021 announcement of a definitive agreement to acquire PRA Health Sciences for approximately USD 12 billion, further strengthening ICON's footprint in key ASEAN economies like Singapore.

Growth Drivers

Government support for pharmaceutical R&D is a major catalyst. Singapore, in particular, has been an active investor in pharmaceutical innovation since the early 1990s. The Singapore government allocated USD 16 billion under its Research, Innovation, and Enterprise (RIE) Plan from 2011 to 2015, followed by a further commitment of USD 19 billion for the RIE2020 Plan covering 2016 to 2020. These sustained investments have positioned Singapore as a leading regional R&D hub, attracting significant CDMO activity.

The ongoing U.S.-China trade tensions are also reshaping the global CDMO supply chain in ways that benefit ASEAN. As tariffs between the U.S. and China have escalated, contract manufacturers are seeking alternative production locations. ASEAN countries — particularly Malaysia, Indonesia, and Vietnam — are emerging as natural alternatives, bolstered by corporate tax structures comparable to China's and active efforts to build robust pharmaceutical supply chains.

Restraining Factors

The primary impediment to market growth is the limited regulatory compliance of many ASEAN facilities. Access to markets in the U.S. and Europe requires manufacturing sites to hold EU-GMP or PIC/S-GMP accreditation. A significant proportion of ASEAN facilities currently operate only at the WHO-GMP standard. Vietnam exemplifies this gap — as of the CPhI South East Asia Report 2020, only 17 of its facilities held EU-GMP or PIC/S-GMP certifications, compared to 222 facilities operating under the lower-tier WHO-GMP standard. This compliance shortfall limits export potential and restricts access to higher-tier domestic hospital procurement contracts.

Market Segmentation

By Service Type, the CMO (Contract Manufacturing Organization) segment holds the largest revenue share, driven by the cost advantage of ASEAN manufacturing relative to Western markets and strong trade incentives offered to foreign investors. The API (Active Pharmaceutical Ingredient) sub-segment, within CMO services, is a key contributor. The CRO (Contract Research Organization) segment, meanwhile, is the fastest-growing, led by Singapore's mature pharmaceutical market and Thailand's emergence as a preferred location for multinational clinical trials, thanks to its large treatment-naïve patient population across diverse disease profiles.

Connect with Our Expert for any Queries: https://www.fortunebusinessinsights.com/enquiry/speak-to-analyst/106193

Country Insights

Singapore leads the ASEAN CDMO market, attracting the highest share of multinational companies seeking outsourced clinical research, supported by world-class infrastructure and highly qualified research professionals. Thailand holds second place, propelled by government-led healthcare infrastructure initiatives and its growing attractiveness to global pharma players for clinical trials. Malaysia, Indonesia, Philippines, Vietnam, and other ASEAN countries are all expected to post substantial growth over the forecast period, driven by comparatively lower contract manufacturing costs relative to Western markets.

Key Industry Players

The ASEAN CDMO landscape is led by Lonza, Catalent, Inc., Samsung Biologics, Parexel International Corporation, IQVIA, and PPD International, among others. Other notable players include Pfizer CentreOne, Thermo Fisher Scientific (Patheon), Vetter Pharma, Almac Group, CSI Medical Research, and Esco Aster. These organizations are pursuing consolidation strategies and expanding their ASEAN footprints to capitalize on the region's growing pharmaceutical outsourcing potential.